Menu Search
Equities

Asarina Pharma AB (publ)

APS:BER

Asarina Pharma AB (publ)

Actions
  • Price (EUR)0.0808
  • Today's Change0.00 / 0.00%
  • Shares traded-1.00
  • 1 Year change-12.36%
  • Beta--
Data delayed at least 15 minutes, as of May 09 2024 18:35 BST.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Profile data is unavailable for this security.

About the company

Asarina Pharma AB (publ), formerly Umecrine Mood, is a Sweden-based biotech company within area of women’s health. The Company’s main product is Sepranolone, a treatment for Premenstrual dysphoric disorder (PDD), a form of Premenstrual syndrome (PMS). Sepranolone (UC1010) is an endogenous compound occurring naturally in the brain. Sepranolone inhibits the effects of allopregnanolone, the steroid that causes PMDD. Moreover, Sepranolone is applicable for treatment of menstrual migraine. Additionally to clinical trials with sepranolone, the Company develops a sepranolone analog that is a similar substance, which allows for alternative administration. The Company conducts trials in Europe. The Company’s main shareholders are Kurma Biofund and The Foundation for Baltic and East European Studies.

  • Revenue in SEK (TTM)0.00
  • Net income in SEK-12.91m
  • Incorporated2006
  • Employees--
  • Location
    Asarina Pharma AB (publ)Karolinska Institutet Science ParkFogdevreten 2SOLNA 171 65SwedenSWE
  • Phone+46 852484482
  • Websitehttps://asarinapharma.com/
More ▼
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.